Buy Ranbaxy, says Kunal Saraogi

Kunal Saraogi of Equityrush feels that one should buy Ranbaxy.

Saraogi told CNBC-Awaaz, "Investors should buy Ranbaxy at the level of Rs 423. The US FDA has given a nod to sell Lipitor to the company. The stock can touch Rs 525-550 in future."
The company's trailing 12-month (TTM) EPS was at Rs -6.79 per share. (Sep 2011). The stock's price-to-earnings (P/E) ratio was -. The latest book value of the company is Rs 121.48 per share. At current value, the price-to-book value of the company was 3.71. The dividend yield of the company was 0.44%.